PAG’s private equity strategy, along with consortium partners CX Partners and Samara Capital, has completed the acquisition of a controlling stake in the Optimus Group, through the API platform, Sekhmet Pharmaventures, the companies said in a joint statement.
Nikhil Srivastava, Partner and Managing Director, Head, India Private Equity, PAG, commented in the statement, “………We look forward to supporting Optimus to continue to invest in its R&D, manufacturing capabilities and Intellectual Property (IP) management, and serve the health needs of people in India and across the globe.”
PAG views India as a particularly attractive market. With this transaction, it has invested more than $700 million in private equity in India over the last two years across multiple sectors. Founded in 2004, Optimus is a vertically integrated manufacturer of pharma products including advanced intermediates, Active Pharmaceutical Ingredients (APIs) and finished drugs. It currently exports more than 100 products to 40 countries, the statement concluded.